Silhouette score is unsuitable as a metric for single-cell data integration.

Transcriptome-scale maps of RNA secondary structure ensembles in living cells detect candidate RNA structural switches.

Matched ribosome profiling and RNA sequencing data quantify translation efficiency patterns across 140 human and mouse cell lines.

A graph neural network framework enables individualized genetic risk prediction at the single-cell level.

RNA-binding motifs in eukaryotic proteins are presented in a comprehensive resource.

A deep convolutional neural network model predicts the influence of the full-length mRNA sequence on translation efficiency.

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Vilya Therapeutics is designing macrocycle drug candidates.

Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Freya Biosciences is restoring balance in the vaginal microbiome to improve pregnancy outcomes.

Inspired by natural molecular glues, drug hunters are chasing protein–protein interactions with next-gen small molecules tuned for enhanced tissue specificity and reduced toxicity.

For decades, and in the exceptional instance of the Institut Pasteur for over a century, non-profit organizations have augmented R&D to advance scientific understanding and develop affordable and accessible pipelines of vaccines, medicines and diagnostics. Small and medium enterprises and former biopharmaceutical industry executives make a sizeable contribution to global health goals by pursuing opportunities in this corner of the global biopharmaceutical ecosystem.